Media stories about Halyard Health (NYSE:HYH) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Halyard Health earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.7983474388973 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Several brokerages recently issued reports on HYH. Stephens upgraded Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. BidaskClub upgraded Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Zacks Investment Research cut Halyard Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Stifel Nicolaus reiterated a “buy” rating and set a $52.00 target price on shares of Halyard Health in a research report on Friday, November 3rd. Finally, ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Halyard Health currently has a consensus rating of “Buy” and a consensus price target of $44.00.

Shares of Halyard Health (HYH) traded up $0.88 during trading hours on Wednesday, hitting $46.67. The stock had a trading volume of 287,600 shares, compared to its average volume of 350,179. The stock has a market cap of $2,190.00, a price-to-earnings ratio of 21.91, a price-to-earnings-growth ratio of 2.47 and a beta of 1.69. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19. Halyard Health has a fifty-two week low of $35.24 and a fifty-two week high of $50.99.

Halyard Health (NYSE:HYH) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The business had revenue of $401.40 million for the quarter, compared to analyst estimates of $394.54 million. During the same quarter in the previous year, the company earned $0.48 EPS. The company’s quarterly revenue was up 1.0% on a year-over-year basis. sell-side analysts expect that Halyard Health will post 2.08 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/22/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-halyard-health-hyh-share-price.html.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.